Today, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee is meeting to discuss the biologics license application for the Alzheimer’s drug donanemab.
The advisory panel will review the safety and dosing of the experimental drug and how patients are chosen for treatment.
The committee will vote on whether the data from the clinical trials shows that this drug, made by Eli Lilly, effectively treats Alzheimer’s and whether the benefits outweigh the risks.
If approved, donanemab will be the third amyloid-targeted drug to come to market. One of the previous two, lecanemab, received full approval from the FDA last year.
As the Lord Leads, Pray with Us…
- For the members of the panel to be discerning in their review of the data and results of the drug trials.
- For HHS and FDA officials as they address American health issues and solutions.
- For prudence for the president and U.S. health advisors as the administration weighs the adoption of World Health Organization policies and standards.
